Eversept Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Eversept Partners’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-100,000	Closed	-$9.27M	–	82
2024 Q2	$9.27M	Buy	+100,000	New	+$8.97M	0.63%	29
2023 Q4	–	Sell	-20,000	Closed	-$1.46M	–	70
2023 Q3	$1.46M	Buy	+20,000	New	+$1.6M	0.12%	63
2023 Q1	–	Sell	-216,087	Closed	-$17.9M	–	80
2022 Q4	$17.9M	Buy	216,087 +116,087	+116%	+$9.4M	1.57%	15
2022 Q3	$7.93M	Sell	100,000 -256,067	-72%	-$21.6M	0.69%	31
2022 Q2	$26.4M	Buy	+356,067	New	+$26.7M	1.88%	14

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Eversept Partners's XBI Position: Q3 2024 in Review

Eversept Partners sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2024, closing a stake of 100,000 shares — an estimated $9.27M sold.

Eversept Partners first reported a position in XBI in Q2 2022 and held it in 5 quarters. The position peaked at $26.4M in Q2 2022. 769 funds tracked by Wall St. Rank hold XBI as of Q3 2024.

Eversept Partners reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2024 after selling out during the quarter.
Eversept Partners sold 100,000 State Street SPDR S&P Biotech ETF shares in Q3 2024, an estimated $9.27M.
Eversept Partners first reported a position in State Street SPDR S&P Biotech ETF in Q2 2022 and held it in 5 quarters.
Eversept Partners's State Street SPDR S&P Biotech ETF position peaked at $26.4M in Q2 2022.
769 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2024.

Based on Eversept Partners's 13F filing for Q3 2024, filed 14 Nov 2024.